What was the primary driver of the significant increase in net income this quarter?

The substantial increase in net income was primarily driven by the completion of the sale of Edwards Lifesciences' Critical Care product group. This divestiture generated a pre-tax gain of $3.3 billion, which significantly boosted the reported net income for the period. Excluding this one-time gain, the core operational performance would show a more modest increase in profitability.

How did the recent acquisitions impact the company's financial position and strategy?

The acquisitions of Endotronix, Inc. and JC Medical, Inc. were strategic moves to bolster Edwards Lifesciences' presence in critical areas. Endotronix expands the company's reach into implantable sensors for heart failure management, a growing therapeutic area. JC Medical enhances the Transcatheter Aortic Valve Replacement (TAVR) portfolio, aiming to treat patients with aortic regurgitation. These acquisitions are reflected in increased intangible assets and goodwill on the balance sheet and signal the company's commitment to investing in growth technologies aligned with its core mission.

What are the potential risks or uncertainties highlighted in this filing?

The company continues to face uncertainties related to ongoing tax matters, including significant disputes with the IRS regarding transfer pricing, and a notice of assessment from the Israel Tax Authority. While the company believes its provisions are adequate and intends to contest these matters vigorously, adverse outcomes could materially impact financial results. Additionally, ongoing litigation, including a recent securities class action lawsuit, represents another area of potential financial and operational risk.

How has the divestiture of the Critical Care business affected the company's financial reporting?

The sale of the Critical Care product group has led to its results being reflected as 'discontinued operations' in the consolidated financial statements for all periods presented. This includes the historical revenues, expenses, and the significant gain on sale. This reclassification allows investors to better assess the performance of the company's ongoing structural heart and related businesses, distinguishing them from the divested segment.

EW 10-Q Quarterly Report Q3 FY2024 — Revenue, Net Income, EPS

Summary

Edwards Lifesciences Corporation (EW) reported a strong third quarter and nine-month period ending September 29, 2024, characterized by significant revenue growth and strategic divestitures. The company's core structural heart business demonstrated robust performance, with net sales increasing by 8.9% for the quarter and 8.3% for the nine months, driven by strong demand for its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) products. A major highlight was the completion of the sale of its Critical Care product group for $4.2 billion, which contributed a substantial gain to net income and allows the company to sharpen its focus on implantable medical innovations. Financially, the company reported a significant increase in net income, largely influenced by the gain from the Critical Care divestiture. Operating income also showed positive trends, reflecting disciplined expense management and strong sales. The company also made strategic acquisitions, including Endotronix, Inc. and JC Medical, Inc., to further strengthen its heart failure and structural heart portfolios, respectively. Despite these strategic moves and operational successes, investors should remain aware of ongoing litigation and tax matters that could present future uncertainties.

Financial Highlights

50 data points

Beta

Revenue

$1.35B

0.8% Gross Margin

Net Income

$3.07B

2.3% Net Margin

EPS (Diluted)

$5.13

Total Assets

$12.97B

Cash & Equivalents

$3.68B

Free Cash Flow

$299.90M

Financial Statements

Beta

Revenue	$1.35B
Cost of Revenue	$262.90M
Gross Profit	$1.09B
R&D Expenses	$253.40M
SG&A Expenses	$421.40M
Operating Income	$350.60M
Net Income	$3.07B
EPS (Basic)	$5.14
EPS (Diluted)	$5.13
Shares Outstanding (Basic)	597.20M
Shares Outstanding (Diluted)	598.10M

Key Highlights

1Net sales increased by 8.9% year-over-year for the third quarter to $1.35 billion and by 8.3% for the first nine months to $4.05 billion, driven by Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) product sales.
2Completed the sale of the Critical Care product group for $4.2 billion, resulting in a pre-tax gain of $3.3 billion recognized in discontinued operations, significantly boosting net income.
3Acquired Endotronix, Inc. for $798.8 million to expand into the heart failure management space and JC Medical, Inc. for $116.3 million to enhance its Transcatheter Aortic Valve Replacement (TAVR) portfolio.
4Gross profit as a percentage of net sales saw a slight increase in the third quarter driven by foreign currency impacts and timing of expenses, though it decreased slightly for the nine-month period due to currency fluctuations.
5Operating income from continuing operations increased for both the three months ($350.6 million) and nine months ($1.07 billion) ended September 30, 2024, indicating strong core business profitability.
6Total assets grew to $12.97 billion from $9.36 billion at year-end 2023, primarily due to increased cash and investments following the divestiture and strategic acquisitions, as well as significant increases in Goodwill and Other Intangible Assets from business combinations.
7The company ended the quarter with a strong liquidity position, with cash and cash equivalents and short-term investments totaling $4.45 billion.

Edwards Lifesciences Corp Quarterly Report for Q3 Ended Sep 30, 2024

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions